Regeneron Pharmaceuticals, Inc. (REGN)
Nasdaq · Healthcare · Biotechnology
$726.47−1.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $74.8B
- P/E (trailing)
- 18.0
- Forward P/E
- 11.8
- Dividend yield
- 0.5%
- 52-week range
- $541.00 – $859.34
- 52-week change
- +26.05%
- EPS (trailing)
- $40.44
- Analyst rating
- 1.9 Buy
- Next earnings
- Oct 30, 2026
Fiscal year to Dec 2025
- Revenue
- $14.3B (+0.99%)
- Net income
- $4.5B
- Operating margin
- 24.9%
- Diluted EPS
- $41.48
- Free cash flow
- $4.1B
From the company’s annual report on SEC EDGAR.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc.
Headquarters: Tarrytown, United States · 15,410 employees · regeneron.com